AstraZeneca moving from Schleswig-Holstein to Hamburg
AstraZeneca is moving its German headquarters from Wedel to Hamburg-Bahrenfeld in late April. The relocation to the site of a former marzipan factory should put the company on a growth course following job cuts last year. Plans are being laid to grow the workforce substantially in the coming months, the company said.
New office, jobs and work concept
AstraZeneca intends to create around 90 new jobs in various fields and to establish an activity-based working concept and thus attract new talent. Alexandra Bishop, Managing Director of AstraZeneca Germany, remarked: "Working practices have evolved and our new environment offers the best in technology, flexible workspaces that can be adapted to different needs, and an office space that meets our sustainability requirements as a growing company." The more central location would make it easier to network with partners in Hamburg including the Life Science Nord and Gesundheitswirtschaft Hamburg (GWHH) clusters and the Health Innovation Port.
Boosting Hamburg as a centre of innovation
AstraZeneca Deutschland had growth of 25 per cent and generated total sales of around EUR 950 million in 2021. The company employs more than 900 people nationwide. Michael Westhagemann, Senator for Economics termed the healthcare sector a "catalyst of research, an economic factor and job engine for the Hanseatic city," which AstraZeneca continues to push ahead. Healthcare is a focal point of the senate's Regional Innovation Strategy (RIS) to drive the development of innovative and sustainable solutions for key parts of society and forward-looking sectors. Emphasis is on health, climate and energy, mobility, data science and digitalisation as well as material sciences and new materials.
AstraZeneca GmbH is the German subsidiary of the British-Swedish pharmaceutical company AstraZeneca PLC. The global, science-driven biopharmaceutical company focuses on the discovery, development and commercialization of prescription medicines in oncology, rare diseases and biopharmaceuticals, including cardiovascular, renal and metabolic, and respiratory and immunology. Headquartered in Cambridge, Britain, The group operates in more than 100 countries and is headquartered in Cambridge, Britain.